Royal Bank Of Canada restated their buy rating on shares of Epizyme, Inc. (NASDAQ:EPZM) in a report released on Friday morning. Royal Bank Of Canada currently has a $20.00 target price on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Epizyme and gave the stock a buy rating in a research note on Monday, June 5th. Zacks Investment Research raised shares of Epizyme from a hold rating to a buy rating and set a $16.00 target price for the company in a research note on Wednesday, July 12th. Cann reaffirmed a buy rating and issued a $26.00 target price on shares of Epizyme in a research note on Wednesday, June 21st. ValuEngine raised shares of Epizyme from a sell rating to a hold rating in a research note on Saturday, June 24th. Finally, HC Wainwright reaffirmed a buy rating on shares of Epizyme in a research note on Friday, May 19th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $23.38.
Epizyme (EPZM) traded up 7.50% during trading on Friday, reaching $17.20. 1,900,596 shares of the company were exchanged. The firm’s market cap is $1.01 billion. Epizyme has a 52-week low of $8.38 and a 52-week high of $18.80. The firm has a 50-day moving average of $15.11 and a 200-day moving average of $15.17.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. Epizyme’s revenue for the quarter was up 2027.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.49) earnings per share. On average, equities analysts forecast that Epizyme will post ($2.39) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Epizyme, Inc. (EPZM) Receives Buy Rating from Royal Bank Of Canada” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/09/16/epizyme-inc-epzm-receives-buy-rating-from-royal-bank-of-canada.html.
In other news, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction on Friday, June 30th. The shares were sold at an average price of $15.50, for a total transaction of $46,872.00. Following the completion of the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at $628,199.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00. Following the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at approximately $298,744.32. The disclosure for this sale can be found here. Insiders have sold 48,024 shares of company stock valued at $706,722 in the last three months. 25.20% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of EPZM. Palo Alto Investors LLC increased its position in shares of Epizyme by 57.8% during the first quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock worth $82,167,000 after acquiring an additional 1,755,255 shares in the last quarter. State Street Corp boosted its holdings in Epizyme by 59.6% during the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after purchasing an additional 658,727 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Epizyme during the second quarter worth $9,726,000. Oracle Investment Management Inc. acquired a new position in Epizyme during the first quarter worth $8,866,000. Finally, Bain Capital Public Equity Management LLC acquired a new position in Epizyme during the second quarter worth $4,331,000. 83.74% of the stock is owned by institutional investors.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.